SparkCures

Personalized Clinical Trial Support. #myeloma #mds #ntrk

[International Myeloma Foundation @IMFmyeloma]

How do I join a clinical trial for relapsed myeloma? Dr. @jmikhaelmd, Chief Medical Officer of the IMF, answers in this new video. Find a clinical trial at https://t.co/XeN78jWZV6 Watch the full video with Dr. Joe at https://t.co/YvERU376PO

#AsktheIMF #mmsm @SparkCures

[International Myeloma Foundation @IMFmyeloma]

Join IMF Chief Medical Officer @jmikhaelmd, @SparkCures founder Brian McMahon, & myeloma patient advocate @TGood_MYeloma for our Facebook LIVE Q&A on Saturday, July 19 at 10:15am PST! RSVP now so you don’t miss out: https://t.co/Nw5ozYA8im
#AsktheIMF #mmsm

[International Myeloma Foundation @IMFmyeloma]

Don't miss your chance to ask YOUR questions LIVE on Sat. 7/19 @ 10:15am PST! IMF CMO @jmikhaelmd, @SparkCures founder Brian McMahon, & myeloma patient advocate @TGood_MYeloma break down #myeloma clinical trials in this 30-min power session. RSVP: https://t.co/b6XrsLL6W5

#mmsm

[International Myeloma Foundation @IMFmyeloma]

Don't miss your chance to ask YOUR questions LIVE on Sat. 7/19 @ 10:15am PST! IMF CMO @jmikhaelmd, @SparkCures founder Brian McMahon, & myeloma patient advocate @TGood_MYeloma break down #myeloma clinical trials in this 30-min power session. RSVP: https://t.co/b6XrsLL6W5

#mmsm

[SparkCures @SparkCures]

@CiccioCarrezza @IMFmyeloma Hi Ciccio - MGUS is a precursor condition to myeloma - or as @jmikhaelmd explains in his wonderful video "it's the earliest part of the spectrum of multiple myeloma" https://t.co/1tl0Z5blWl @IMFmyeloma

[International Myeloma Foundation @IMFmyeloma]

Visit https://t.co/XeN78jWZV6 to start searching today! Or get even more personalized options when you create an account on https://t.co/HmGkOPxCju #ash24 #imfash24

@SparkCures

[SparkCures @SparkCures]

@MidAtlanticMSG @IMFsupport @Sylviads4 You were missed!!!

[SparkCures @SparkCures]

The Siteman Cancer Center is an international leader in cancer treatment, research, prevention, education and community outreach. It is the only cancer center in Missouri to hold the prestigious Comprehensive Cancer Center designation. https://t.co/oZM8KAgQjK

[SparkCures @SparkCures]

CC-220 is a immunomodulator being developed by Celgene Corporation. CD-220, also called iberdomide, binds the protein Cereblon which is one of the mechanisms of action for the immunomodulator drugs. Learn more:
https://t.co/BQwe6R9Syw #myeloma #clinicaltrial #mmsm

[SparkCures @SparkCures]

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple #Myeloma Who Have Had an Autologous Stem Cell Transplant #clinicaltrial #mmsm
https://t.co/Oc675YmEig

[SparkCures @SparkCures]

A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple #Myeloma https://t.co/msf3BWHMIr #clinicaltrial #mmsm

[SparkCures @SparkCures]

Let us do the heavy lifting for you. Add trials and treatment centers to your list of favorites in your profile and we'll send you alerts to keep you informed of any new updates that are made. Create your account today: https://t.co/G2iKwnmDXr #myeloma #clinicaltrial #mmsm

[SparkCures @SparkCures]

The team at the Barbara Ann Karmanos Cancer Institute is entirely focused on treating hematologic malignancies and shares its expertise to create a customized treatment plan for each patient. Learn more: #myeloma #clinicaltrial #mmsm
https://t.co/pPISEevY2N

[SparkCures @SparkCures]

Monoclonal Antibodies are treatments that use your immune system function to fight cancer. Antibodies are cloned and used to attack one specific type of protein found in cancer https://t.co/v0ZEjNaIBD learn more visit: https://t.co/rOsC6YNzkS #myeloma #clinicaltrial #mmsm

[SparkCures @SparkCures]

Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple #Myeloma https://t.co/o8pYKqOWje #clinicaltrial #mmsm

[SparkCures @SparkCures]

This Phase I study is designed to determine the safety and find the recommended Phase 2 dose of Belantamab Mafodotin in patients with high-risk smoldering multiple #myeloma. https://t.co/3iKaS8hZUp #clinicaltrial #mmsm

[SparkCures @SparkCures]

Did you know there are over a dozen clinical trials available for patients with Smoldering "Asymptomatic" #Myeloma? We can help you evaluate smoldering trials that may be right for you. https://t.co/OHKHJXcj8I #clinicaltrial #mmsm

[SparkCures @SparkCures]

The mission of the NCI-designated Sidney Kimmel Cancer Center is to improve the lives of cancer patients and their families through innovation, compassion, and breakthrough discoveries. For more information, visit: https://t.co/XfoXj83vMS #myeloma #clinicaltrial #mmsm

[SparkCures @SparkCures]

Elranatamab is a bi-specific antibody used in the treatment of multiple #myeloma. It works by binding to both CD3 on T cells and BCMA expressed on malignant plasma cells. Learn more about this therapy and associated clinical trials: https://t.co/vXabWcyKBp #clinicaltrial #mmsm

[SparkCures @SparkCures]

Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple #Myeloma.
https://t.co/4tImuiQYfg #clinicaltrial #mmsm